Skip to main content
. 2017 Apr 11;7:831. doi: 10.1038/s41598-017-00860-y

Figure 2.

Figure 2

Kaplan–Meier estimates probability of being free of any relapse by AQP4-IgG serostatus after tacrolimus treatment. Kaplan–Meier analysis revealed that there was a significant difference between the high titer (≥1:64) group of aquaporin 4 antibody (AQP4-IgG) in the serum and the low titer group(<1:64 or none) regarding relapses while undergoing tacrolimus therapy (P = 0.028 by log-rank test).